Comparing radiofrequency endometrial ablation, uterine artery embolization, and hysterectomy for adenomyosis-related heavy bleeding
Official title: Radiofrequency Endometrial Ablation or Uterine Artery Embolization for Women With Adenomyosis-related Abnormal Uterine Bleeding Eligible for Hysterectomy: a Non-inferiority Randomized Clinical Trial Comparing Each Intervention to Hysterectomy
Run by University Hospital, Bordeaux · NCT07195305 · Data updated 2026-11-12
This trial will test whether radiofrequency endometrial ablation or uterine artery embolization can reduce heavy menstrual bleeding, pain, and improve quality of life compared with hysterectomy in people with adenomyosis.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 30 Years to 50 Years |
| Sex | Women only |
| Enrollment | 230 (estimated) |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 4 sites (Bordeaux and 3 other locations) |
| Status | Recruiting |
| Started | April 17, 2026 |
| Main results expected | May 2029 |
| Study ends | May 2029 |
| Registry record updated | April 20, 2026 |
| Trial ID | NCT07195305 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are premenopausal women aged 30–50 with MRI-confirmed adenomyosis, PBAC >100, uterine size 6–12 cm, and who have failed, cannot take, or refuse medical therapy and are willing to consider hysterectomy or uterus-sparing procedures.
✕Probably not a fit
Patients who desire future fertility, have major uterine cavity abnormalities, extensive deep infiltrating endometriosis, or large/multiple fibroids beyond the study criteria are unlikely to benefit from the procedures studied.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter interventional study enrolls premenopausal women with MRI-confirmed adenomyosis and significant abnormal uterine bleeding who have failed or declined medical therapy. Participants receive one of three procedures—radiofrequency endometrial ablation (RFA), uterine artery embolization (UAE), or hysterectomy—and are followed for outcomes up to two years. Key outcomes include menstrual blood loss (PBAC), pelvic pain, quality of life, procedure-related complications, and recovery metrics. The goal is to compare the effectiveness and safety of uterus-sparing options versus hysterectomy for symptom control.
Why it matters
Potential benefit: If successful, the study could identify uterus-sparing procedures that control bleeding and pain while avoiding or delaying hysterectomy and shortening recovery time.
How similar studies have gone: UAE has established efficacy for symptomatic fibroids with high satisfaction at two years and RFA has shown modest bleeding and safety benefits in benign AUB, but direct head-to-head comparisons versus hysterectomy specifically for adenomyosis remain limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Premenopausal women aged 30 to 50 years * Women who had at least 3 prior months failed medical therapy, or a contraindication to medical therapy, or refused medical therapy for adenomyosis-related AUB * Symptomatic pure internal adenomyosis or dominant adenomyosis (with less than 5 concurrent uterine fibroids type 3-7 \< 5 cm) confirmed by MRI (\< 6 months) according to ESHRE criteria * AUB defined as a PBAC score \>100 at baseline * Uterine ultrasound measurement of 6.0-12.0 cm (external os to internal fundus) * Women with an indication for hysterectomy for adenomyosis-related AUB and accepting hysterectomy * Highly effective contraception for women of childbearing potential, maintained until the onset of menopause * Affiliated or beneficiary of health insurance * Signed informed consent Exclusion Criteria: * Uterine cavity abnormality or obstruction confirmed via imaging modalities or hysteroscopy * Deep infiltrating posterior subperitoneal endometriosis involving contiguous digestive tract structures * Uterine malignancy within the last five years * Secreting ovarian tumor * Atypical endometrial hyperplasia * Unaddressed high grade cervical intra-epithelial lesions * Active sexually transmitted disease or pelvic inflammatory disease * Documented or suspected coagulopathies or long-term blood-thinner medications * Prior transmural myomectomy or prior endometrial ablation * Plasma FSH level \> 40 IU/mL * Any contraindication to angiography (including iodine allergy and creatinine clearance \< 60mL/min) * Any contraindication to MRI (claustrophobia, pace maker, etc.) * Any contraindication to the use of Embosphere®, Embozene® or NovaSure® according to the instruction for use * Women who are pregnant, breastfeeding, or who are planning to become pregnant * Any condition or any situation that would prohibit women from coming to the investigational center for the 6 months follow-up * Women unable to understand the nature, risks, significance and implications of the clinical investigation * Women under legal protection
Where it's running
-
CHU Montpellier
Montpellier, France Recruiting -
CHU Bordeaux
Bordeaux, France Not yet recruiting -
APHP - Hôpital Antoine Béclère
Clamart, France Not yet recruiting -
CHU Limoges
Limoges, France Not yet recruiting
Study contacts
- Study coordinator: Jean-Luc Brun, MD, PhD
- Email: jean-luc.brun@chu-bordeaux.fr
- Phone: +33 5 56 79 59 85
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Glaucoma and Brain Changes: How Brain Structure and Size See What Glaucoma Is Doing
This study tests whether glaucoma is linked to broader brain changes by comparing brain MRI and eye health over time in people with glaucoma and matched controls.
-
Who’s at high risk after RCC surgery? Real-world clues from French registry
This study looks at real-world data from French RCC patients who had local or high-risk locally advanced disease to see how they do after surgery and how doctors decide on adjuvant treatment.
-
Prediction score for death or lung transplant in emphysema caused by alpha-1 antitrypsin deficiency
This study tests a new prediction tool to identify people with emphysema due to alpha-1-antitrypsin deficiency who are at high risk of death or needing a lung transplant.
-
Frailty score predicts quality of life after emergency heart surgery in people 75 and older
This study tests whether a preoperative frailty score can predict quality of life one year after emergency heart surgery in patients aged 75 and up.
-
Evolution of spinal care practices in Bordeaux
This study will track how care for spine conditions changes over five years by collecting data from adults treated for spinal issues at a Bordeaux hospital.
-
Feeding-jejunostomy nutrition during pre-surgery treatment for esophagus or stomach cancer
This study tests whether giving nutrition through a jejunostomy tube during pre-surgery (neoadjuvant) treatment helps reduce complications after surgery for malnourished people with esophageal or stomach cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.